6 January 2020 - The PBAC is set to consider 45 submissions (20 major & 25 minor) at its next scheduled meeting in March.

The Committee will consider two reports from the Drug Utilisation Subcommittee (DUSC) for medicines for:

• Multiple myeloma (1 medicine)
• Pain (multiple medicines)
• Idiopathic pulmonary fibrosis (2 medicines)
• Androgen deficiency (multiple medicines)

13 (29%) of the 45 submissions are for a new medicine.

15 (33%) of the 45 submissions are resubmissions; most are for a new medicine or a new indication.

A quarter of all submissions are for oncology medicines.

MSD and Roche are the leading applicants.

All agenda items have been entered in MAESTrO.

Read agenda for March 2020 PBAC meeting

Looking for more insights? Contact us for a more detailed analysis of the agenda.